The right dose of progesterone depends almost entirely on why you’re taking it. A woman using progesterone to protect her uterine lining during menopause hormone therapy typically takes 200 mg of oral micronized progesterone per day for 12 to 14 days each month, while a woman trying to prevent preterm birth might use a much lower vaginal dose daily for weeks. The route of delivery, the clinical goal, and individual absorption all shift the number, which is why no single milligram figure answers the question honestly.
Progesterone for Menopausal Hormone Therapy
If you have an intact uterus and you’re taking estrogen for menopausal symptoms, you need a progestogen alongside it. Estrogen alone thickens the uterine lining over time, raising the risk of endometrial hyperplasia and, eventually, endometrial cancer. Progesterone’s job here is to counteract that effect. The most studied regimen uses oral micronized progesterone at 200 mg per day, given cyclically for 12 to 14 days each month. A systematic review found this dose provides adequate endometrial protection for up to five years of use.1PubMed. The impact of micronized progesterone on the endometrium: a systematic review
Not everyone follows a cyclic schedule. Continuous combined regimens, where you take a lower dose of progesterone every single day alongside estrogen, are popular because they tend to eliminate monthly withdrawal bleeding. Cyclic therapy using lower estrogen doses has its own appeal: it minimizes your progestin exposure and tends to produce fewer side effects like breast tenderness.2PubMed. HRT dosing regimens: continuous versus cyclic-pros and cons The trade-off is that cyclic use at higher estrogen doses often comes with scheduled bleeding, which some women find acceptable and others do not.
Vaginal progesterone is another option for menopausal women. A study of 136 women tested a vaginal progesterone gel (45 mg daily) in both cyclic and continuous schedules alongside estrogen. In the cyclic group, over 90% experienced predictable withdrawal bleeding. In the continuous group, about 80% had no bleeding at all over six months. No cases of endometrial hyperplasia appeared in either group.3Human Reproduction. Vaginal progesterone in menopause: Crinone® 4% in cyclical and constant combined regimens These are substantially lower milligram amounts than the oral route, which makes sense once you understand how the vaginal route delivers progesterone differently to the uterus.
Why the Route Changes the Dose
When you swallow a progesterone capsule, it passes through the digestive system and liver before reaching the bloodstream. The liver metabolizes a large fraction of it on that first pass, which is why oral progesterone historically had a reputation for poor bioavailability and why micronization (grinding the hormone into tiny particles) was developed to improve absorption.4Best Practice & Research Clinical Obstetrics & Gynaecology. Progesterone: History, facts, and artifacts Even with micronization, oral doses need to be relatively high (100 to 300 mg) because so much is lost to liver metabolism.
Vaginal progesterone bypasses most of that liver metabolism. It also benefits from what researchers call the “uterine first-pass effect,” a phenomenon where drugs absorbed through the vaginal wall travel preferentially to the uterus via local blood vessel transfer. A pharmacokinetic study of a 100 mg vaginal progesterone tablet found it produced meaningful uterine tissue concentrations even though blood levels were modest.5Steroids. Pharmacokinetics of the progesterone-containing vaginal tablet and its use in assisted reproduction Research in postmenopausal women confirmed that the uterine artery receives a disproportionate share of vaginally absorbed drugs, supporting the rationale for lower vaginal doses when the target organ is the uterus itself.6Human Reproduction. Uterine first pass effect in postmenopausal women
This is why a 45 mg vaginal gel can protect the endometrium while an oral capsule needs 200 mg to do the same job. It’s also why you shouldn’t assume that a dose you read about for one route applies to another. If your doctor switches you from oral to vaginal progesterone, expect the milligram number to drop substantially.
Progesterone During IVF and Fertility Treatment
Progesterone supplementation is considered a standard part of IVF and other assisted reproductive technology cycles. The ovary’s natural progesterone production after ovulation can be disrupted by the medications used to stimulate egg development, so external progesterone fills the gap during the luteal phase (the window between embryo transfer and a pregnancy test).7PubMed Central. Progesterone and the luteal phase: a requisite to reproduction
Vaginal progesterone is the most common route for IVF luteal support, typically given as capsules or gel. A subcutaneous injection of 25 mg per day has also been shown to work as well as vaginal preparations in large pooled analyses of clinical trials.8PLOS ONE. Subcutaneous Progesterone Is Effective and Safe for Luteal Phase Support in IVF: An Individual Patient Data Meta-Analysis of the Phase III Trials The specific dose varies by clinic protocol, but vaginal capsules are commonly prescribed at 200 mg two or three times daily, while vaginal gels deliver 90 mg per application once or twice daily.
One detail that matters in frozen embryo transfer cycles: your blood progesterone level on the day of transfer is a better predictor of success than the dose on your prescription pad. Research found that women with serum progesterone below a certain threshold on transfer day had meaningfully lower ongoing pregnancy rates compared with women above it.9Reproductive BioMedicine Online. Progesterone levels on pregnancy test day after hormone replacement therapy-cryopreserved embryo transfer cycles and related reproductive outcomes Encouragingly, a woman’s progesterone response to a given dose tends to be consistent from one cycle to the next, which means a low level on one transfer can guide a dose increase for the next attempt.10PubMed. Intra-individual variability of serum progesterone levels on the day of frozen blastocyst transfer in hormonal replacement therapy cycles
Preventing Miscarriage in Early Pregnancy
This is one of the more complicated areas of progesterone dosing because the overall evidence and the subgroup evidence tell different stories. The large PRISM trial randomized over 4,000 women with bleeding in early pregnancy to receive either vaginal micronized progesterone (400 mg twice daily) or placebo. Looking at all women together, live birth rates were not significantly different: about 75% in the progesterone group and 72% in the placebo group.11PubMed. A Randomized Trial of Progesterone in Women with Bleeding in Early Pregnancy
But when researchers looked specifically at women who had both a history of previous miscarriage and current pregnancy bleeding, the picture changed. In that subgroup, progesterone improved the live birth rate from about 70% to 75%. For women with three or more prior miscarriages plus current bleeding, the benefit was more pronounced: a live birth rate of roughly 72% with progesterone versus 57% with placebo.12PubMed Central. Micronized vaginal progesterone to prevent miscarriage: a critical evaluation of randomized evidence The dose used in these trials was 400 mg vaginally twice daily, started as early as possible after bleeding began and continued through 16 weeks of gestation.
The practical takeaway: if you’re experiencing first-trimester bleeding and have a history of miscarriage, the evidence favors using vaginal progesterone at 800 mg total per day. If you have no history of miscarriage, the benefit is much less clear.
Preventing Preterm Birth
A separate body of research addresses progesterone for women at risk of preterm delivery, primarily those found to have a short cervix on ultrasound. Here the doses are lower and the route is almost always vaginal. A multicenter trial found that vaginal progesterone gel given to women with a cervix measuring 10 to 20 mm roughly halved the rate of preterm birth before 33 weeks compared with placebo.13PubMed Central. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix Another trial using 200 mg vaginal progesterone capsules nightly found that spontaneous delivery before 34 weeks dropped from about 34% in the placebo group to roughly 19% in the progesterone group.14PubMed. Progesterone and the Risk of Preterm Birth among Women with a Short Cervix
An evidence-based review concluded that compelling data supports vaginal progesterone for reducing preterm birth and improving newborn outcomes in singleton pregnancies with a short cervix (25 mm or less), whether or not the woman has a history of preterm delivery.15PubMed Central. Vaginal progesterone for the prevention of preterm birth: who can benefit and who cannot? The typical dose in these studies is 90 mg vaginal gel or 200 mg vaginal capsule daily, started in the second trimester and continued to around 36 weeks. This is markedly different from the 800 mg daily used in miscarriage trials, reflecting the different clinical problem and different gestational timing.
Treating Endometrial Hyperplasia
When the uterine lining grows too thick, progesterone can be used to reverse the overgrowth. A study comparing different oral micronized progesterone doses for non-atypical endometrial hyperplasia found that 200 mg daily produced remission in roughly 92 to 98% of cases with both simple and complex forms. The 100 mg dose was less effective, particularly for complex hyperplasia, while 300 mg did not add much benefit over 200 mg.16PubMed. Treatment of simple and complex endometrial non-atypical hyperplasia with natural progesterone: response rate to different doses Treatment was given cyclically and typically lasted at least three months, with longer durations and at least medium doses appearing to produce the best outcomes for atypical forms of hyperplasia.17PubMed Central. Progestin Therapy of Complex Endometrial Hyperplasia With and Without Atypia
Side Effects and the Sedation Question
The most commonly reported side effect of oral progesterone is drowsiness, and it’s not subtle. When progesterone is taken by mouth, the liver converts a portion of it into allopregnanolone, a metabolite that acts on the same brain receptors targeted by sedative medications.18PubMed Central. Tolerance to allopregnanolone with focus on the GABA-A receptor In a controlled study, a 400 mg oral dose significantly increased sedation and slowed eye movement speed compared with placebo.19Psychoneuroendocrinology. Oral progesterone decreases saccadic eye velocity and increases sedation in women This is why doctors typically recommend taking oral progesterone at bedtime. Some women actually welcome the sedating effect if they struggle with sleep, while others find it bothersome even at night.
Vaginal progesterone produces far less allopregnanolone because it largely bypasses liver metabolism. If sedation is a problem on the oral route, switching to vaginal delivery at an equivalent endometrial-protective dose often resolves it. Other side effects can include bloating, headache, and breast tenderness, though these tend to be milder with micronized progesterone than with synthetic progestins.
One practical tip: taking oral progesterone with food increases absorption.20PubMed. The absorption of oral micronized progesterone: the effect of food, dose proportionality, and comparison with intramuscular progesterone This can be a double-edged sword. Better absorption means more of the hormone reaches your system, but it can also amplify the sedation. If you’re newly starting and unsure how it will affect you, taking it with a small bedtime snack is a reasonable approach.
Progesterone Versus Synthetic Progestins and Breast Cancer Risk
One reason micronized progesterone has gained popularity over synthetic progestins like medroxyprogesterone acetate is the apparent difference in breast cancer risk. A systematic review and meta-analysis found that women using estrogen combined with natural progesterone had about a third lower risk of breast cancer compared with women using estrogen combined with synthetic progestins.21PubMed Central. Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis An expert panel review concluded that estrogen combined with micronized progesterone does not appear to increase breast cancer risk when used for up to five years, but limited evidence suggests that use beyond five years may carry some increased risk.22PubMed. The impact of micronized progesterone on breast cancer risk: a systematic review
The metabolic profile also looks reassuring. In a clinical trial of early postmenopausal women, adding micronized progesterone to transdermal estradiol did not adversely affect blood pressure, blood sugar, insulin levels, HDL cholesterol, triglycerides, or inflammatory markers. Total cholesterol and LDL cholesterol actually improved.23PubMed Central. Effects of micronized progesterone added to non-oral estradiol on lipids and cardiovascular risk factors in early postmenopause: a clinical trial This doesn’t mean progesterone is harmless at any dose for any duration, but it does suggest a more favorable safety profile than older synthetic alternatives.
Progesterone for Premenstrual Symptoms
Despite the logic that supplementing progesterone might ease premenstrual syndrome (PMS), the clinical evidence here is disappointing. A systematic review of trials comparing progesterone (given orally or vaginally) to placebo found no clinically important difference in PMS symptom relief.24PubMed. Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review This remains one of the more common misunderstandings: many women believe that PMS is caused by “low progesterone” and that supplementing it should help. The reality is more complex, with current thinking leaning toward sensitivity to normal hormonal fluctuations rather than absolute hormone deficiency as the driver of premenstrual mood symptoms.25PubMed Central. Using estrogen and progesterone to treat premenstrual dysphoric disorder, postnatal depression and menopausal depression
If your doctor prescribes progesterone and your primary goal is PMS relief, it’s worth having a frank conversation about the evidence. The hormone may still be appropriate for other reasons (irregular cycles, endometrial protection), but expecting it to fix premenstrual symptoms specifically may set you up for frustration.
Progesterone in Feminizing Hormone Therapy
Progesterone is sometimes added to estrogen-based feminizing hormone therapy for transgender women, though its role is less established than in menopausal care. The rationale draws on its effects in cisgender women: it may contribute to later stages of breast development, exert some anti-androgen activity, and offer potential long-term bone and cardiovascular benefits.26PubMed Central. Progesterone in gender-affirming therapy of trans women A small study found that transgender women who received progesterone reported significantly greater satisfaction with breast development at six and nine months compared with those who did not.27Journal of the American Pharmacists Association. Effects of progesterone on gender affirmation outcomes as part of feminizing hormone therapy
Doses in this context are usually 100 to 200 mg oral micronized progesterone daily, often taken at bedtime. The evidence base remains thin compared with progesterone’s use in menopause or pregnancy, and most clinical recommendations acknowledge this by describing progesterone in gender-affirming care as an area where more research is needed before firm dosing guidelines can be set.
How Your Body’s Own Progesterone Production Changes Over Time
Your ovaries don’t produce the same amount of progesterone at every stage of life. A study measuring daily progesterone levels across regularly menstruating women aged 18 to 44 found that luteal progesterone peaked in the 25-to-34 age range, with the lowest levels at the youngest (18 to 19) and oldest (40 to 44) ends of the spectrum.28Journal of Biosocial Science. Normative study of age variation in salivary progesterone profiles This pattern closely mirrors the well-known age curve of fertility.
After menopause, ovarian progesterone production essentially ceases, which is why exogenous progesterone becomes necessary for any woman taking estrogen therapy. But even before menopause, women in their late 30s and early 40s may have lower progesterone than they did a decade earlier. This decline can contribute to shorter luteal phases, irregular cycles, and heavier periods, and it’s sometimes the underlying reason a doctor recommends cyclic progesterone supplementation well before menopause arrives. Understanding this natural trajectory helps explain why progesterone dosing isn’t just a question of milligrams but also of timing within your reproductive life.